Evidence map›Paper›PMID 38482244›Full record

ArticleJournal of gastrointestinal oncology2024

Hongjiang Pu, Shuai Zhang, Shan Yan, Chunxia Li, Jiangping Fu, Dingyun You, Tao Zhang, Zhenhui Li

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of gastrointestinal oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Hongjiang Pu *Department of Oncology, Dazhou Central Hospital, Dazhou, China.
Shuai Zhang *Department of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China.
Shan Yan *Yunnan Key Laboratory of Stem Cell and Regenerative Medicine, School of Biomedical Engineering Research, Kunming Medical University, Kunming, China.
Chunxia LiDepartment of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China.
Jiangping FuDepartment of Oncology, Dazhou Central Hospital, Dazhou, China.
Dingyun YouYunnan Key Laboratory of Stem Cell and Regenerative Medicine, School of Biomedical Engineering Research, Kunming Medical University, Kunming, China.
Tao ZhangDepartment of Biostatistics, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China.
Zhenhui LiDepartment of Radiology, the Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Kunming, China.
Kunming Medical University · CNShandong University · CNDazhou Central Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Adjuvant chemotherapy is considered for stage II colorectal cancer (CRC) patients with poor prognostic risk factors. However, current stratification algorithms are still insufficient to identify high-risk patients. Methods: We conducted a screening strategy to define ZNF326 based on quantitative proteomics in 11 paired CRC patients selected by a nested case-control design, and tested the association between Results: We found that low Conclusions:

Indexed as

adjuvant chemotherapycolorectal cancer (CRC)prognostic markerproteomicsZNF326

Identifiers

PMID38482244
PMCPMC10932666
OpenAlexW4392301556

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.